NASDAQ:AKER

Akers Biosciences (AKER) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.53
$2.93
50-Day Range
$2.47
$4.59
52-Week Range
$1.65
$6.97
Volume
104,455 shs
Average Volume
769,876 shs
Market Capitalization
$47.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKER stock logo

About Akers Biosciences Stock (NASDAQ:AKER)

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.

AKER Stock News Headlines

The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Cam Akers Becomes A Free Agent
The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Jennifer C. Akers
See More Headlines
Receive AKER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2018
Today
4/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:AKER
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-3,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.58 million
Book Value
$5.38 per share

Miscellaneous

Free Float
N/A
Market Cap
$47.63 million
Optionable
Not Optionable
Beta
0.30
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Christopher C. Schreiber (Age 56)
    CEO, Pres & Director
    Comp: $507.62k
  • Mr. Ian Rhodes (Age 48)
    Interim Chief Financial Officer
  • Mr. Gary M. Rauch (Age 65)
    VP of Fin. & Treasurer

AKER Stock Analysis - Frequently Asked Questions

How were Akers Biosciences' earnings last quarter?

Akers Biosciences, Inc. (NASDAQ:AKER) released its earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share for the quarter. The medical instruments supplier earned $0.56 million during the quarter.

What is Thomas A. Nicolette's approval rating as Akers Biosciences' CEO?

3 employees have rated Akers Biosciences Chief Executive Officer Thomas A. Nicolette on Glassdoor.com. Thomas A. Nicolette has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioPharma (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

This page (NASDAQ:AKER) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners